Antimalarial drug resistance.
暂无分享,去创建一个
[1] N. White,et al. Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[2] N. White,et al. Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[3] B. Greenwood,et al. Mass administrations of antimalarial drugs. , 2003, Trends in parasitology.
[4] M. Kolczak,et al. The effect of dual infection with HIV and malaria on pregnancy outcome in western Kenya , 2003, AIDS.
[5] W. Peters. Chemotherapy and drug resistance in malaria. 2nd edition. Vols 1 and 2continued. , 1987 .
[6] S. Siziya,et al. Association of HIV infection with the development of severe and complicated malaria cases at a rural hospital in Zimbabwe. , 2000, The Central African journal of medicine.
[7] D E EYLES,et al. Infectivity to mosquitoes of Plasmodium falciparum as related to gametocyte density and duration of infection. , 1955, The American journal of tropical medicine and hygiene.
[8] T. Smith,et al. Attributable fraction estimates and case definitions for malaria in endemic areas. , 1994, Statistics in medicine.
[9] J. Verdrager. Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia. , 1986, The Journal of tropical medicine and hygiene.
[10] S. Krishna,et al. Artemisinins target the SERCA of Plasmodium falciparum , 2003, Nature.
[11] R. Price,et al. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[12] K. Marsh. Malaria disaster in Africa , 1998, The Lancet.
[13] X. Su,et al. Complex Polymorphisms in an ∼330 kDa Protein Are Linked to Chloroquine-Resistant P. falciparum in Southeast Asia and Africa , 1997, Cell.
[14] L. Aarons,et al. Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection , 2002, Parasitology.
[15] N. White,et al. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo , 1997, Antimicrobial agents and chemotherapy.
[16] B. Levin,et al. The population dynamics of antimicrobial chemotherapy , 1997, Antimicrobial agents and chemotherapy.
[17] N. French,et al. Childhood malaria in a region of unstable transmission and high human immunodeficiency virus prevalence , 2003, The Pediatric infectious disease journal.
[18] N. White,et al. The de novo selection of drug–resistant malaria parasites , 2003, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[19] H. Webster,et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. , 1996, The American journal of tropical medicine and hygiene.
[20] C. Shulman,et al. Importance and prevention of malaria in pregnancy. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[21] X. Su,et al. Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa. , 1997, Cell.
[22] N. White,et al. Clinical Pharmacokinetics and Pharmacodynamics of Artemether-Lumefantrine , 1999 .
[23] R. Douglas,et al. Plasmodium species (malaria). , 1990 .
[24] J. Meuwissen,et al. Feeding behaviour and sporozoite ejection by infected Anopheles stephensi. , 1991, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[25] Richard N. Price,et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study , 2000, The Lancet.
[26] Q. Cheng,et al. Mutations in Plasmodium falciparumCytochrome b That Are Associated with Atovaquone Resistance Are Located at a Putative Drug-Binding Site , 2000, Antimicrobial Agents and Chemotherapy.
[27] N. White. The assessment of antimalarial drug efficacy. , 2002, Trends in parasitology.
[28] D. Warhurst,et al. The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[29] S. Kyes,et al. Antigenic variation at the infected red cell surface in malaria. , 2001, Annual review of microbiology.
[30] N. White,et al. Clearance kinetics of parasites and pigment-containing leukocytes in severe malaria. , 1996, Blood.
[31] W. Watkins,et al. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[32] N. White,et al. The evolution of drug-resistant malaria: the role of drug elimination half-life. , 2002, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[33] P. G. Shute,et al. A Study of Induced Malignant Tertian Malaria , 1932, Proceedings of the Royal Society of Medicine.
[34] P. Rathod,et al. Variations in frequencies of drug resistance in Plasmodium falciparum. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[35] R. Rosenberg,et al. An estimation of the number of malaria sporozoites ejected by a feeding mosquito. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[36] A. Cowman,et al. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[37] W. Peters,et al. The prevention of antimalarial drug resistance. , 1990, Pharmacology & therapeutics.
[38] P. Bloland,et al. Combination therapy for malaria in Africa: hype or hope? , 2000, Bulletin of the World Health Organization.
[39] N. White,et al. Antimalarial pharmacokinetics and treatment regimens. , 1992, British journal of clinical pharmacology.
[40] P. Newton,et al. A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. , 2003, Molecular biology and evolution.
[41] V. Yu,et al. Antimicrobial Therapy and Vaccines , 1999 .
[42] Thomas Lavstsen,et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A‐adhering Plasmodium falciparum involved in pregnancy‐associated malaria , 2003, Molecular microbiology.
[43] A. Cowman,et al. Chemotherapy and drug resistance in malaria. , 1990, International journal for parasitology.
[44] François Nosten,et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number , 2004, The Lancet.
[45] T. Triglia,et al. Amplification of the multidrug resistance gene pfmdr1 in Plasmodium falciparum has arisen as multiple independent events , 1991, Molecular and cellular biology.
[46] C. Curtis,et al. A simple model of the build-up of resistance to mixtures of anti-malarial drugs. , 1986, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[47] E. Lagarde,et al. Impact of chloroquine resistance on malaria mortality. , 1998, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.
[48] B. Sharp,et al. Antifolate antimalarial resistance in southeast Africa: a population-based analysis , 2003, The Lancet.
[49] N. Fairley,et al. Sidelights on malaria in man obtained by subinoculation experiments. , 1947, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[50] C. Plowe,et al. More on 'the efficacy of antifolate antimalarial combinations in Africa'. , 1999, Parasitology today.
[51] R. Anderson,et al. Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[52] S. Lindsay,et al. Short-range attractiveness of pregnant women to Anopheles gambiae mosquitoes. , 2002, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[53] M. Lemnge,et al. Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity. , 2003, The American journal of tropical medicine and hygiene.
[54] K. Kirk,et al. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum , 2000, Nature.
[55] C. Plowe,et al. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. , 2002, The Journal of infectious diseases.
[56] J. Beier,et al. Treatment failure of pyrimethamine‐sulphadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya , 2003, Tropical medicine & international health : TM & IH.
[57] N. White,et al. Antimalarial drug resistance and combination chemotherapy. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[58] W. Peters. Drug resistance in malaria--a perspective. , 1969, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[59] C. Plowe. Monitoring antimalarial drug resistance: making the most of the tools at hand , 2003, Journal of Experimental Biology.
[60] U. d’Alessandro,et al. Modelling a predictable disaster: the rise and spread of drug-resistantmalaria. , 2000, Parasitology today.
[61] Geneva,et al. ANTIMALARIAL DRUG COMBINATION THERAPY Report of a WHO Technical Consultation , 2022 .
[62] R. Snow,et al. Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. , 2003, The Lancet. Infectious diseases.